請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58249
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 翁啟惠(Chi-Huey Wong) | |
dc.contributor.author | Juway Lin | en |
dc.contributor.author | 林周緯 | zh_TW |
dc.date.accessioned | 2021-06-16T08:09:19Z | - |
dc.date.available | 2014-07-22 | |
dc.date.copyright | 2014-07-22 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-05-05 | |
dc.identifier.citation | Reference
1. Luo A, He X, Zhou S, Fan Y, He T, et al. (2009) In vitro antioxidant activities of a water-soluble polysaccharide derived from Dendrobium nobile Lindl. extracts. Int J Biol Macromol 45: 359-363. 2. Wang X, Luo J, Chen R, Zha X, Wang H The effects of daily supplementation of Dendrobium huoshanense polysaccharide on ethanol-induced subacute liver injury in mice by proteomic analysis. Food & Function. 3. Luo J-P, Deng Y-Y, Zha X-Q (2008) Mechanism of Polysaccharides from Dendrobium huoshanense. on Streptozotocin-Induced Diabetic Cataract. Pharmaceutical Biology 46: 243-249. 4. Zha X-Q, Luo J-P, Jiang S-T (2007) Induction of Immunomodulating Cytokines by Polysaccharides from Dendrobium huoshanense. Pharmaceutical Biology 45: 71-76. 5. Meng LZ, Lv GP, Hu DJ, Cheong KL, Xie J, et al. (2013) Effects of polysaccharides from different species of Dendrobium (Shihu) on macrophage function. Molecules 18: 5779-5791. 6. Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2: 907-916. 7. Hsieh YS, Chien C, Liao SK, Liao SF, Hung WT, et al. (2008) Structure and bioactivity of the polysaccharides in medicinal plant Dendrobium huoshanense. Bioorg Med Chem 16: 6054-6068. 8. Shima C, Adachi Y, Minamino K, Okigaki M, Shi M, et al. Neuroprotective effects of granulocyte colony-stimulating factor on ischemia-reperfusion injury of the retina. Ophthalmic Res 48: 199-207. 9. Hsu HY, Hua KF, Lin CC, Lin CH, Hsu J, et al. (2004) Extract of Reishi polysaccharides induces cytokine expression via TLR4-modulated protein kinase signaling pathways. J Immunol 173: 5989-5999. 10. Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, et al. (1997) The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 70: 699-705. 11. Lin YL, Liang YC, Lee SS, Chiang BL (2005) Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and p38 mitogen-activated protein kinase pathways. J Leukoc Biol 78: 533-543. 12. Lin KI, Kao YY, Kuo HK, Yang WB, Chou A, et al. (2006) Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1. J Biol Chem 281: 24111-24123. 13. Lai CY, Hung JT, Lin HH, Yu AL, Chen SH, et al. Immunomodulatory and adjuvant activities of a polysaccharide extract of Ganoderma lucidum in vivo and in vitro. Vaccine 28: 4945-4954. 14. Kupper TS, Chua AO, Flood P, McGuire J, Gubler U (1987) Interleukin 1 gene expression in cultured human keratinocytes is augmented by ultraviolet irradiation. J Clin Invest 80: 430-436. 15. Orelio C, Peeters M, Haak E, van der Horn K, Dzierzak E (2009) Interleukin-1 regulates hematopoietic progenitor and stem cells in the midgestation mouse fetal liver. Haematologica 94: 462-469. 16. Weber A, Wasiliew P, Kracht M Interleukin-1 (IL-1) pathway. Sci Signal 3: cm1. 17. van den Berg WB (2001) Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 3: 18-26. 18. Brennan FM (2001) A follow-up to 'Anti-cytokine therapy in chronic destructive arthritis' by Wim B van den Berg. Arthritis Res 3: 211-213; discussion 214-215. 19. Stylianou E, O'Neill LA, Rawlinson L, Edbrooke MR, Woo P, et al. (1992) Interleukin 1 induces NF-kappa B through its type I but not its type II receptor in lymphocytes. J Biol Chem 267: 15836-15841. 20. Seckinger P, Williamson K, Balavoine JF, Mach B, Mazzei G, et al. (1987) A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol 139: 1541-1545. 21. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR (1987) A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 139: 1546-1549. 22. Seckinger P, Dayer JM (1987) Interleukin-1 inhibitors. Ann Inst Pasteur Immunol 138: 486-488. 23. Balavoine JF, de Rochemonteix B, Williamson K, Seckinger P, Cruchaud A, et al. (1986) Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 78: 1120-1124. 24. Dinarello CA (1994) The interleukin-1 family: 10 years of discovery. Faseb J 8: 1314-1325. 25. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 266: 10331-10336. 26. Thompson RC, Dripps DJ, Eisenberg SP (1991) IL-1ra: properties and uses of an interleukin-1 receptor antagonist. Agents Actions Suppl 35: 41-49. 27. Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16: 27-55. 28. Irikura VM, Lagraoui M, Hirsh D (2002) The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type I IL-1 receptor. J Immunol 169: 393-398. 29. Fischer E, Van Zee KJ, Marano MA, Rock CS, Kenney JS, et al. (1992) Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79: 2196-2200. 30. Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77: 1627-1652. 31. Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12: 404-410. 32. Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL, et al. (1992) Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 112: 188-193; discussion 193-184. 33. McCarthy PL, Jr., Abhyankar S, Neben S, Newman G, Sieff C, et al. (1991) Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78: 1915-1918. 34. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, et al. (2000) Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 43: 2648-2659. 35. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39: 797-809. 36. Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF (2000) Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. J Bone Miner Res 15: 402-414. 37. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404: 398-402. 38. So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9: R28. 39. Hagaman DD, Okayama Y, D'Ambrosio C, Prussin C, Gilfillan AM, et al. (2001) Secretion of interleukin-1 receptor antagonist from human mast cells after immunoglobulin E-mediated activation and after segmental antigen challenge. Am J Respir Cell Mol Biol 25: 685-691. 40. Malyak M, Smith MF, Jr., Abel AA, Hance KR, Arend WP (1998) The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol 161: 2004-2010. 41. Darragh J, Ananieva O, Courtney A, Elcombe S, Arthur JS MSK1 regulates the transcription of IL-1ra in response to TLR activation in macrophages. Biochem J 425: 595-602. 42. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147. 43. Hua KF, Hsu HY, Chao LK, Chen ST, Yang WB, et al. (2007) Ganoderma lucidum polysaccharides enhance CD14 endocytosis of LPS and promote TLR4 signal transduction of cytokine expression. J Cell Physiol 212: 537-550. 44. Dinarello CA Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732. 45. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, et al. (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84: 114-122. 46. Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, et al. (2009) The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol 183: 4705-4714. 47. Duff GW, Atkins E, Malawista SE (1983) The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes. Trans Assoc Am Physicians 96: 234-245. 48. Terkeltaub R Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 6: 30-38. 49. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, et al. (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110: 851-860. 50. Mandrup-Poulsen T, Pickersgill L, Donath MY Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6: 158-166. 51. Chen X, Hu ZP, Yang XX, Huang M, Gao Y, et al. (2006) Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int Immunopharmacol 6: 499-508. 52. Wei M, Jiang ST, Luo JP (2007) Enhancement of growth and polysaccharide production in suspension cultures of protocorm-like bodies from Dendrobium huoshanense by the addition of putrescine. Biotechnol Lett 29: 495-499. 53. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, et al. (2002) Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 10: 1057-1062. 54. Gabay C, Smith MF, Eidlen D, Arend WP (1997) Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 99: 2930-2940. 55. Pruitt JH, Welborn MB, Edwards PD, Harward TR, Seeger JW, et al. (1996) Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 87: 3282-3288. 56. Prieur AM, Kaufmann MT, Griscelli C, Dayer JM (1987) Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 2: 1240-1242. 57. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, et al. (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37: 1744-1751. 58. De Benedetti F, Pignatti P, Massa M, Sartirana P, Ravelli A, et al. (1995) Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 13: 779-784. 59. EM ON, Puri P, Reen DJ (1993) Early induction of IL-1 receptor antagonist (IL-1Ra) in infants and children undergoing surgery. Clin Exp Immunol 93: 218-222. 60. Grzelak I, Olszewski WL, Zaleska M, Durlik M, Lagiewska B, et al. (1996) Blood cytokine levels rise even after minor surgical trauma. J Clin Immunol 16: 159-164. 61. Arend WP (1993) Interleukin-1 receptor antagonist. Adv Immunol 54: 167-227. 62. Lennard AC (1995) Interleukin-1 receptor antagonist. Crit Rev Immunol 15: 77-105. 63. Fisher CJ, Jr., Slotman GJ, Opal SM, Pribble JP, Bone RC, et al. (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12-21. 64. Fisher CJ, Jr., Dhainaut JF, Opal SM, Pribble JP, Balk RA, et al. (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. Jama 271: 1836-1843. 65. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, et al. (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4: 353-360. 66. Flo TH, Halaas O, Lien E, Ryan L, Teti G, et al. (2000) Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol 164: 2064-2069. 67. Guthridge CJ, Eidlen D, Arend WP, Gutierrez-Hartmann A, Smith MF, Jr. (1997) Lipopolysaccharide and Raf-1 kinase regulate secretory interleukin-1 receptor antagonist gene expression by mutually antagonistic mechanisms. Mol Cell Biol 17: 1118-1128. 68. Dreyer MG, Juge-Aubry CE, Gabay C, Lang U, Rohner-Jeanrenaud F, et al. (2003) Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor kappa B/PU.1 binding site. Biochem J 370: 591-599. 69. Vey E, Dayer JM, Burger D (1997) Direct contact with stimulated T cells induces the expression of IL-1beta and IL-1 receptor antagonist in human monocytes. Involvement of serine/threonine phosphatases in differential regulation. Cytokine 9: 480-487. 70. Ohmori Y, Smith MF, Jr., Hamilton TA (1996) IL-4-induced expression of the IL-1 receptor antagonist gene is mediated by STAT6. J Immunol 157: 2058-2065. 71. Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D (2005) The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol 174: 2974-2980. 72. Miyazaki T, Nishijima M (1981) Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chem Pharm Bull (Tokyo) 29: 3611-3616. 73. Gao Y, Gao H, Chan E, Tang W, Xu A, et al. (2005) Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunol Invest 34: 171-198. 74. Liao SF, Liang CH, Ho MY, Hsu TL, Tsai TI, et al. Immunization of fucose-containing polysaccharides from Reishi mushroom induces antibodies to tumor-associated Globo H-series epitopes. Proc Natl Acad Sci U S A 110: 13809-13814. 75. Anthony RM, Rutitzky LI, Urban JF, Jr., Stadecker MJ, Gause WC (2007) Protective immune mechanisms in helminth infection. Nat Rev Immunol 7: 975-987. 76. Hsu MJ, Lee SS, Lee ST, Lin WW (2003) Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from Ganoderma lucidum. Br J Pharmacol 139: 289-298. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58249 | - |
dc.description.abstract | 摘要
霍山石斛是一個珍貴且富有多功能性的中草藥,具有預防癌症以及抗發炎的傳聞。然而,此中草藥之免疫活性探討目前僅限於在體外研究中少量細胞激素(Cytokine)及趨化素(Chemokine)的研究。在我們的研究中,第一,探討了從霍山石斛萃取的多醣體對老鼠的活體實驗或是人類免疫細胞中,所誘發一系列的細胞激素或趨化素的表現。我們發現石斛多醣在老鼠活體以及人類免疫細胞中,可以誘導包括第一型輔助型T細胞之細胞激素,第二型輔助型T細胞之細胞激素,發炎性細胞激素以及趨化素。第二,我們證明了在老鼠活體中實驗中石斛多醣可以刺激脾臟細胞的增生,也刺激增生了包括CD4 T細胞、CD8 T細胞、B細胞、自然殺手細胞、自然殺手T細胞、單核細胞、巨噬細胞、顆粒型細胞以及調控型T細胞等多種免疫細胞。在我們的研究中還發現了值得注意的一點,也就是石斛多醣可以在老鼠活體以及人類免疫細胞中,特別是單核細胞,誘導一種抗發炎物質稱為細胞激素1(IL-1)接受器的拮抗蛋白(IL-1 receptor antagonist, IL-1ra)。石斛多醣在老鼠血清中誘發的IL-1ra含量超過了細胞激素1β(IL-1β)多達10倍以上,這現象顯示了IL-1ra所引導之抗發炎反應會勝過IL-1β引導的發炎反應。在石斛多醣所誘導IL-1ra之訊息傳遞鏈上,我們證明了ERK/ELK,p38MAPK,PI3K以及NFκB有扮演重要的角色。最後,我們比較並發現了石斛多醣所誘發之IL-1ra的量顯著的超越了F3(F3是一種從另一相當受歡迎之中草藥靈芝所萃取出來之多醣體)所誘發的量。這些結果顯示了石斛多醣對於舒緩IL-1所造成的免疫疾病上,有著巨大的應用價值。 | zh_TW |
dc.description.abstract | Abstract
Dendrobium huoshanense is a valuable and versatile Chinese herbal medicine with the anecdotal claims of cancer prevention and anti-inflammation. However, its immunological activities are limited to in vitro studies on a few cytokines and immune cell functions. First, we investigated the effects of polysaccharides isolated from DH (DH-PS) on inducing a panel of cytokines/chemokines in mice in vivo and human in vitro. We found that DH polysaccharides (DH-PS) induced TH1, TH2, inflammatory cytokines and chemokines in mouse in vivo and human cells in vitro. Secondly, we demonstrated that DH-PS expanded mouse splenocytes in vivo including CD4+ T cells, CD8+ T cells, B cells, NK cells, NKT cells, monocytes/macrophages, granulocytes and regulatory T cells. Notably, DH-PS induced an anti-inflammatory molecule, IL-1ra, in mouse and human immune cells, especially monocytes. The serum level of IL-1ra elicited by the injection of DH-PS was over 10 folds of IL-1β, suggesting that DH-PS-induced anti-inflammatory activities might over-ride the inflammatory ones mediated by IL-1β. The signaling pathways of DH-PS-induced IL-1ra production was shown to involve ERK/ELK, p38 MAPK, PI3K and NFκB. Finally, we observed that IL-1ra level induced by DH-PS was significantly higher than that by F3, a polysaccharide extract isolated from another popular Chinese herbal medicine, Ganoderma lucidum. These results indicated that DH-PS might have potential applications for ameliorating IL-1-induced pathogenic conditions. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T08:09:19Z (GMT). No. of bitstreams: 1 ntu-103-F94b46033-1.pdf: 1239182 bytes, checksum: 54769a46b8906a2e610a4a04d67bbd38 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 目 錄
中文摘要……………………………………………………………………………. 6 英文摘要……………………………………………………………………………. 8 第一章 INTRODUCTION……………………………………………………….10 1.1 Biological activities of Dendrobium …………………………………………….10 1.2 Immune-modulating effects of Dendrobium huoshanense ……………………...11 1.3 Immunoregulatory effects of Ganoderma lucidum………………………………12 1.4 IL-1 signaling in immune system…………………………………………………13 1.5 IL-1 receptor antagonist…………………………………………………………..15 1.6 IL-1 mediated pathogenic conditions and targeting therapy………………………16 第二章 RESULTS……………………………………………………………………19 2.1 DH-PS induced the secretions of multiple cytokines and chemokines in vivo……19 2.2 DH-PS expanded and activated subpopulations of immune cells in vivo…………20 2.3 DH-PS induced the productions of multiple cytokines and chemokines in human immune cells…………………………………………………………………..22 2.4 Dose-dependency of IL-1ra induction by DH-PS in mice………………………...23 2.5 DH-PS induced IL-1ra secretion in human monocytes but not neutrophils………23 2.6 Intracellular signaling of DH-PS-induced IL-1ra production in monocytes………25 2.7 DH-PS induced larger amounts of IL-1ra than F3 (G. lucidum) ………………….26 第三章 DISCUSSION ………………………………………….……………………28 第四章 MATERIALS AND METHODS……….…………………………………..33 4.1 Ethics statement……………………………………………………………………33 4.2 Preparations for crude polysaccharide extracts from Dendrobium huoshanense (DH-PS) ……………………………………………………………………………….33 4.3 Cell culture and reagents…………………………………………………………...33 4.4 RNA isolation and RT-PCR………………………………………………………..34 4.5 Animal experiments and flow cytometric analysis…………………………………35 4.6 Measurements of cytokines, chemokines and IL-1ra………………………………36 4.7 Validation of viability or the proliferation of THP-1 cells…………………………37 4.8 Statistical analysis………………………………………………………………….38 參考文獻…………………………………………………………………….…… …...75 圖目錄 Figure.1 DH-PS elicited the productions of cytokines and chemokines in vivo….39 Figure.2 DH-PS expanded subpopulations of splenocytes……………………….43 Figure.3 DH-PS elicited the productions of cytokines and chemokines in human peripheral blood mononuclear cells (PBMC)……………………………………..47 Figure.4 DH-PS elicited the productions of cytokines and chemokines in human CD14+cells…………………………………………………………………………51 Figure.5 DH-PS induced IL-1ra production in vivo………………………………55 Figure.6 DH-PS induced IL-1ra production in human PBMC, monocytes, but not neutrophils………………………………………………………………………….57 Figure.7 DH-PS dose-dependently induced IL-1ra production in human monocytic cell line THP-1 cells…………………………………………………………………….59 Figure.8 DH-PS induced IL-1ra production through MAPK, PI3K and NF-κB…..61 Figure.9 DH-PS induced more IL-1ra production than F3 in human CD14+ cells and THP-1 cells………………………………………………………………………….64 Figure.S1 Kinase inhibitors were not toxic to THP-1 cells in indicated concentrations……………………………………………………………………….67 Figure.S2 DH-PS promoted the proliferation of THP-1 cells………………………69 Figure.S3 F3 elicited the productions of cytokines and chemokines in human CD14+ cells…………………………………………………………………………………71 | |
dc.language.iso | en | |
dc.title | 探討霍山石斛之免疫多功能性及誘導單核細胞球產生IL-1ra之機轉 | zh_TW |
dc.title | The multifaceted effects of polysaccharides isolated from Dendrobium huoshanense on immune functions with the induction of Interleukin-1 receptor antagonist (IL-1ra) in monocytes | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳鈴津(Alice Lin-Tsing Yu),林國儀(Kuo-I Lin),呂仁(Joyce Jean Lu),張雅貞(Ya-Jen Chang) | |
dc.subject.keyword | 霍山石斛,單核細胞球, | zh_TW |
dc.subject.keyword | Dendrobium huoshanense,monocyte, | en |
dc.relation.page | 81 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-05-05 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 1.21 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。